drugset / Trial / NCT01501487

Summary

Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).

Timeline

Start
2011-10
Primary completion
2016-02
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 6 unknown Intravenous
Comparator Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Comparator Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Comparator Docetaxel Small molecule 75 mg/m2 Intravenous
Comparator Docetaxel Small molecule 100 mg/m2 Intravenous
Comparator Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Comparator Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Comparator Epirubicin Small molecule 75 mg/m2 Intravenous
Comparator Epirubicin Small molecule 100 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 80 mg/m2 Intravenous
Comparator Pertuzumab Monoclonal antibody 420 mg Intravenous
Comparator Trastuzumab Monoclonal antibody 2 mg/kg Intravenous
Comparator Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Comparator fluorouracil Small molecule 500 mg/m2 Intravenous
Comparator Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous
Comparator filgrastim Protein / enzyme biologic

Indications